文献库搜索 | GeneLibs

Incorvaia(L),Santini(D),Matrana(MR),Maruzz... Int J Cancer 2026-08-18

...BRCA1/2 vs. non-BRCA HRR: 16.3 months [95% CI, 13.0-69.6] vs. 14.2 [95% CI, 12.0-22.9; p = 0.681]). Primary refractorine...

Reinert(T),Alshehri(AS),Shafik(A),Lin(CH),... Ther Adv Med Oncol None

...BRCA1/2 or PALB2 testing, while ctDNA is preferred for ESR1 detection. Next-generation sequencing (NGS) is the preferred...

Ahdi(D),Hashemi(S),Gholami(A),Derakhshan(S... Mol Biol Rep 2026-07-30

...BRCA1, TP53, PARP1, ATM, and CHK1 affect the cells' vulnerability to genotoxic stress and contribute to the subtype-spec...

Dossa(F),Metcalfe(K),Ante(Z),Liu(N),Lerner... JAMA Netw Open 2026-07-01

Pathogenic variants in BRCA1 and BRCA2 confer substantial risks of breast and ovarian cancer; however, risk for female i...

Harano(K),Nakao(T),Nishio(S),Katsuda(T),Ta... Clin Cancer Res 2026-07-30

...BRCA1/2-mutated tumors and 42.9% (3/7) in non-BRCA1/2-mutated tumors. PD-L1 expression, tumor mutational burden, and mic...

Irmejs(A),Daneberga(Z),Kiploka(K),Augucevi... Eur J Hum Genet 2026-07-30

Pathogenic variants in BRCA1 and BRCA2 account for the majority of hereditary breast and ovarian cancer (HBOC) cases, an...

Zhao(X),Chen(B),Xu(F),Zhang(J),Yao(Z),Wang... Proc Natl Acad Sci U S A 2026-08-11

...BRCA1/2-deficient cells. These findings uncover a cooperative mechanism by which CIP2A-TOPBP1 dynamically regulates Polθ...

Ruan(G),Li(D),Miao(B) Pak J Pharm Sci 2026-10-00

...BRCA1/2 mutations both significantly improved DFS (p<0.05). Multivariate analysis confirmed TNBC, positive lymph node me...

Zou(Z),Lu(G),Xin(M),Du(Z),Cheng(Z),Wu(S),C... J Med Chem 2026-08-13

...BRCA1-deficient cell lines (SUM149PT, MDA-MB-436, and HCC1937) and the BRCA2-deficient cell line (Capan-1). Mechanistic ...

Hwang(SY),Choi(D),Choi(MJ),Jo(HR),Jeong(JH... Nucleic Acids Res 2026-07-17

...BRCA1/BARD1 play key roles in HR. However, whether and how CTCF cooperates with BRCA1/BARD1 for HR remain poorly underst...